Evaluate the Use of the Foundation Pain Index and the Nutritional Supplement BioPlete™ in Adults With Chronic Pain

Exclusion Criteria

• •1. Participant has uncontrolled hypotension (defined as \<90 mmHg systolic and/or \<60 mmHg diastolic).
• •2. Participant has a medical history of heart disease/cardiovascular disease, kidney disease (dialysis or renal failure), or hepatic impairment.
• •3. Participant has a medical history of previously diagnosed major affective disorder, psychiatric disorder that required hospitalization in the year prior to the screening visit, immune disorder (i.e., HIV/AIDS), a history of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit).
• •4. Participant has a condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data.
• •5. Participant is currently taking any dietary supplement that contains active ingredients known to modulate FPI scoring i.e., any active ingredients in the Test Product.
• •6. Participant received a vaccine for Coronavirus Disease 2019 (COVID-19) or any other vaccination in the last 2 weeks prior to randomization or is planning to receive a vaccination during the study period.
• •7. History of hospitalization or in-patient treatment for depression or any related condition within the past five years prior to screening.
• •8. Is currently pregnant, lactating, or becomes pregnant during the conduct of study.
• •9. Participant has a history of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the potential participant at risk because of participation in the study, or influences the study results or the potential participant's ability to participate in the study.
• •10. Participant has a known sensitivity or allergy to any of the ingredients in the study products.
• •11. Participant has any dietary restriction (e.g., vegans or vegetarians that do not consume gelatin) that prevents the participant from consuming any of the ingredients in the study products.
• •12. Participant has a history of drug or alcohol abuse in the past 12 months prior to screening.
• •13. Participant has received or used a study product in another research study within 28 days prior to baseline/Visit 2.